Review: empagliflozin and nebivolol in aging-related redox and inflammatory pathways
This review examines proposed mechanistic links between empagliflozin, nebivolol and aging-related metabolic and vascular pathways; the evidence comes mainly from experimental disease models, and combined effects in aging have not been directly studied. [1]
Automatic summary · not editorially reviewed
The key findings
The review states that evidence for empagliflozin and nebivolol comes mainly from experimental models of cardiovascular or metabolic disease, not from physiological aging studies. [1]
The authors describe a biologically plausible framework rather than definitive evidence of aging-relevant efficacy. [1]
Direct evidence on the combined effects of both agents in aging is described as unavailable. [1]
The source at a glance
- Study type / format
- Narrative review (abstract)
- Population / context
- Experimental models of cardiovascular or metabolic disease discussed in a review of aging-related pathways; physiological aging populations are not the main evidence source.
- Summary based on
- Study abstract
- Original publication
- July 16, 2026
Aging network targeted by two drugs
The review starts from aging as interconnected disturbances: oxidative stress, chronic inflammation, mitochondrial dysfunction and altered nutrient sensing, together contributing to metabolic and vascular decline. It names dysregulation of the AMPK-mTOR-SIRT1 axis, persistent NF-κB activation, impaired Nrf2-mediated antioxidant defense and mitochondrial redox imbalance as central mechanisms. Empagliflozin, a sodium-glucose cotransporter-2 inhibitor, is described as having effects beyond glucose control, including modulation of AMPK signaling, reduced oxidative stress and suppressed inflammatory activation. Nebivolol, a third-generation β1-selective adrenergic blocker with nitric oxide-mediated vasodilation, is linked to endothelial protection, vascular redox regulation and anti-inflammatory activity.
Supporting source [1]
Proposed framework, not demonstrated efficacy
The review places particular emphasis on reported interactions of both agents with AMPK-mTOR-SIRT1 signaling, Nrf2-dependent antioxidant responses, NF-κB-mediated inflammation, mitochondrial function and endothelial homeostasis. It also compares established aging-relevant candidates, including metformin, rapamycin, resveratrol, GLP-1 receptor agonists, NAD modulators and senolytic strategies, to contextualize the potential relevance and limits of metabolic-vascular pathway modulation. The authors state that the literature supports a biologically plausible framework rather than definitive evidence of aging-relevant efficacy.
Supporting source [1]
Evidence gaps: disease models, no combination data
According to the abstract, current evidence on both agents comes predominantly from experimental models of cardiovascular or metabolic disease rather than from studies of physiological aging. Direct evidence on their combined effects in aging is described as unavailable. The review also lists limitations of the evidence base: a predominance of reductionist experimental approaches, limited translational validation and the absence of direct combinational investigations. It calls for further integrative experimental and translational studies to determine whether coordinated targeting of these pathways could provide meaningful therapeutic benefit in aging and age-associated disorders.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a review of mechanistic literature, not a new study. The evidence described comes mainly from experimental cardiovascular or metabolic disease models, translational validation is described as limited, and direct combination data in aging are described as unavailable.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Al-Mahdawi MA, Fawzi HA, Ibrahim N, Muhammad N. · europepmc.org · July 16, 2026